

Bioverativ

"Not your normal upstart": Building a people strategy for a brand new Biotech

July 26th, 2017

A Unique and Compelling Investment Opportunity

Bioverativ

On February 1st, 2017 Bioverativ successfully launched as an independent, global biotechnology company For shareholders, we've created a unique investment opportunity that includes several key attributes:

- ✓ A strong hemophilia franchise
- ✓ An innovative pipeline
- ✓ Well capitalized with potential to create value
- ✓ Integrated capabilities and a talented team

Bioverativ

Our Vision:

To become the leading hematology rare disease company committed to creating significant progress for patients









2017 Business Priorities



Maximize Potential of ELOCTATE & ALPROLIX



Advance Our Pipeline



Strategic Business
Development





Ensure flexibility, free flow of ideas, and speed of decision-making in a brand new company

Flexibility in organizational model

- ✓ Allow fluid organizational structure
- ✓ Avoid siloed functional hierarchy
- ✓ Minimal Committees
- ✓ People expected to know the business

Key belief that co-location is critical to collaboration and decision-making

- ✓ Open space Huddle Rooms
- ✓ Everyone in same building
- ✓ Open staircase to allow for "bumping" into people
- ✓ Different snacks/events on different floors

Aligning compensation and culture to get people working towards on a long term perspective

Belief that every employee should be a shareholder

- ✓ Alignment of Long Term Incentives at all levels
- ✓ All new hires receive LTI
- ✓ Utilize stock options
- ✓ Team based reward structure (not completed)

Culture

- ✓ Act Now Act Courageously Act Together
- ✓ Development focus on strengths
- ✓ Performance Management no labels and not an annual event – manager's role is to coach on demand
- ✓ Talent Review focused on key leadership successor roles

Q&A